Electronic Logs - The next phase of execution maturity in pharma
Maximising Patient Engagement in Clinical Trials
Elevating Drug Safety
Could a Formal Trust Coefficient Release the Pharmacovigilance Capacity AI Promised
The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Designing and Developing Green Drug Delivery Systems: From natural bioactives to sustainable therapeutics
Associate Professor, Somaiya Institute for Research and Consultancy
Dr Maushmi S Kumar is a Life Sciences Researcher Academician and Translational Drug Discovery Scientist with years of experience across academia and pharmaceutical industry Her research spans drug design marine bioactives chemical biology molecular pharmacology and advanced drug delivery with a strong focus on translating discoveries toward therapeutic development for cancer and neurodegenerative...
Articles
Allosteric Modulation: A Paradigm Shift in Pharmaceutical Innovation
Allostery the regulation of a proteins function through the binding of a molecule at a site distinct from the active site has emerged as a pivotal concept in drug discovery By targeting allosteric sites researchers can modulate protein activity with high specificity potentially reducing offtarget effects and overcoming resistance mechanisms associated with traditional activesite inhibitors This ap...
Research Insights
Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
Ansar A Pathan Clare R Sander Helen A Fletcher Ian Poulton Nicola C Alder Natalie E R Beveridge Kathryn T WhelanAdrian V S Hill Helen McShane Centre for Clinical Vaccinology and Tropical Medicine University of Oxford Churchill Hospita
Case Studies
Unusual Drug Response And Hemodynamics In VA – ECMO : A Drug Case Study
Abstract Maintaining higher sedation in patients undergoing ECMO therapy is crucial Currently no definite sedation strategy has been proposed in the literature as the pharmacokinetics of the medications in these patients is still not clear We would like to report a case of a patient with uncontrollable diverse clinical response to medications during arteriovenou
Techno Trends
China Implements New Regulatory Framework for Biopharmaceutical Innovation
China has announced a comprehensive overhaul of its regulatory policies aimed at fostering innovation in the biopharmaceutical sector
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Determinants of Antimicrobial Resistance (AMR) Research in South East Asia
Raja Chakraverty is a serving Scientist with the Indian Council of Medical Research with a decade long research and teaching career in Pharmaceutical Sciences with 54 publications (186 citations) and a book
Doctoral Scholar, Department of Pharmaceutical Technology
Meaningful Advances in Virtual Cells
Brita Belli is an award-winning science and tech writer and Senior Manager of Communications at Recursion, a clinical-stage TechBio company. Her writing has been featured in the New York Times, National Geographic, MSN.com, and Alternet, and she has covered AI drug discovery and other health tech topics for Future Medicine AI, On Drug Delivery, European Biopharmaceutical Review, and OR Manager Magazine. She’s the author of The Autism Puzzle: Connecting the Dots Between Environmental Toxins and Rising Autism Rates (Seven Stories Press).
Nanoemulsion - A Promising Nanocarrier for Dermal Drug Delivery in Psoriasis
Sindhoor S M is currently working as an Assistant Professor in the Department of Pharmaceutics at Sri Adichunchanagiri College of Pharmacy, Mandya, Karnataka. His areas of specialisation include nanotechnology-based drug delivery system, lipid-based formulations, Topical delivery and gastroretentive in situ gel systems. He has published eight papers based on nanotechnology and lipid-based drug delivery system in peer reviewed indexed journals. Presently he is involved in the development of lipid-based delivery systems.
Marina Koland, is Professor and Head of the Department of Pharmaceutics at the NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangalore. Her area of specialisation in research is mucoadhesive and nanoparticulate drug delivery. She has published 50 research papers in peer reviewed journals, presented papers at 10 National and 3 International Conferences and worked on several Nitte University funded projects. She is currently working on solid lipid nanoparticles and micelles as drug carriers for targeting.
The Regulatory Landscape for Nutraceuticals
Suresh Garg is the CMD and Founder of Zeon Life Sciences. He has over 30 years of extensive experience in the fields of nutrition, dairy products, healthcare, and nutraceuticals. Under his leadership, Zeon has become a pioneer in contract manufacturing for nutraceuticals and herbal goods. Owing to his passion and ability to thrive in a variety of sociocultural environments, Zeon has entered international markets.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
